Difference between revisions of "Team:ETH Zurich"
| Line 75: | Line 75: | ||
#second { | #second { | ||
padding-top: 415px; | padding-top: 415px; | ||
| − | padding-bottom: | + | padding-bottom: 700px; |
} | } | ||
| Line 138: | Line 138: | ||
<div id="third"> | <div id="third"> | ||
<center> | <center> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" width=" | + | <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" width="800px"> |
</center> | </center> | ||
</div> | </div> | ||
Revision as of 14:50, 7 October 2017
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.
Project description
